ILAR’s advisory body, the ILAR Council, serves four principal functions:
- to provide program direction and strategic planning;
- to oversee information and communication programs (e.g., the ILAR website and the quarterly ILAR Journal);
- to oversee studies, reports, workshops, and other projects; and
- to direct ILAR’s international programs.
The ILAR Council meets for two days twice annually.
Margaret S. Landi, Chair
Chief of Animal Welfare, Ethics and Strategy
Novartis International AG
Associate Professor of Molecular and Comparative Pathobiology
Johns Hopkins University
Joseph J. DeGeorge
Bianca Holdings, LLC
Scientific Director, Head of Toxicology and Laboratory Animal Medicine
Johnson and Johnson, Janssen Pharmaceuticals
Lewis B. Kinter
Paul A. Locke
Associate Professor, Department of Environmental Health and Engineering
Director, DrPH Program in Environmental Health Sciences
Johns Hopkins Bloomberg School of Public Health
James A. Roth
Clarence Hartley Covault Distinguished Professor
Director, Center for Food Security and Public Health
College of Veterinary Medicine
Iowa State University
Lawrence B. Schook
Edward William and Jane Marr Gutsgell Professor of Animal Sciences and Radiology
University of Illinois at Urbana-Champaign
Dr. Margaret S. Landi is Chief of Animal Welfare, Ethics and Strategy for GlaxoSmithKline. Her role is to provide leadership, guidance, and set policies as Chief Veterinarian for GSK. As Risk Owner for Animals she is responsible to ensure that the quality of animal work is independent of location of study conductance, there is compliance with Corporate Policy 403 on the Care, Welfare and Treatment of Animals, consistency in practices associated with all aspects of the animal care, and use programs where GSK works with animals. Margaret has a VMD and a Masters in Bioethics from the University of Pennsylvania and is a Diplomate in the American College of Laboratory Animal Medicine (ACLAM) and Past-President of the organization. She has worked on review committees of the National Institutes of Health (NIH), has led special site visit teams for NIH committees and is a past ad-hoc member of AAALAC. She is on the Board for the Scientists Center for Animal Welfare and the Chimp Haven Board of Directors. Margaret serves currently as the Chair of the Council for the Institute of Laboratory Animal Research, part of the NASEM. Recent areas of presentations and publications are in the application of global principles for laboratory animals in an international arena with differing laws, cultures, regulations and policies and application of moral considerability in ethical review processes.
Dr. Karin Blumer is a German veterinarian and philosopher, Director of ScienceCommunication and Policy at Novartis International company, located in Basel, Switzerland. After completion of academic studies at the Ludwig-Maximilians-University Munich and the Jesuit Faculty for Philosophy/Munich, she worked as freelance science journalist and policy advisor. In 2001, she joined Novartis International in Basel where she held a variety of different positions in R&D policy, public affairs and science communication. Her professional areas of expertise include digital health, the responsible use of health data, bioethics, animal research, strategic science communication, corporate governance and compliance. She is a member of the European industry’s task force on animal research policies at EFPIA, the European Federation of Pharmaceutical Industries and Associations and co-chair of the Ethics Advisory Board (EAB) of the Human Brain Project, a European Commission Future and Emerging Technologies Flagship project. Karin Blumer authored two interdisciplinary doctorate treatises on the ethics of animal research and the philosophy of risk. She lectures at the University Basel on bioethical issues.
Dr. Cory Brayton is Associate Professor, and Director of Phenotyping and Pathology Core Facility at Johns Hopkins University, School of Medicine. She is a diplomate of the American College of Laboratory Animal Medicine (ACLAM), and of the American College of Veterinary Pathologists (ACVP). She served as president of ACVP in 2014, as well as on ACVP Council 2009-2012, and as president elect, 2013. She received her DVM from Cornell University, and did postdoctoral research and pathology training in New York City at the Animal Medical Center, Cornell University and The Rockefeller University. At The Rockefeller University (1989-1992), she became specifically interested in the pathology and characterization (phenotyping) of genetically engineered mice (GEM), and continued to pursue this interest at several institutions while heading the Facility for Comparative Studies at the Hospital for Special Surgery (1992-1998). At Baylor College of Medicine (1998-2004), she headed the Comparative Pathology Laboratory, and was responsible for health surveillance and diagnostic pathology for a diverse research population including more than 150,000 mice. She also was associate professor in pathology, associate director of the Center for Comparative Medicine, interim attending veterinarian, and served on the IACUC, while pursuing research collaborations, teaching initiatives, and developing national and international conferences on the characterization and pathology of genetically engineered mice. In 2004 she moved to John Hopkins to develop a collaborative phenotyping core based in the Department of Molecular and Comparative Pathobiology (MCP), where veterinarian postdoctoral trainees and faculty investigators provide a unique comparative and translational research resource, in an institution with exceptional resources for multidisciplinary biomedical research. She has been on ILAR council, and CoEIC of ILAR journal since 2012.
Dr. Joseph J. DeGeorge co-founded Bianca Holdings, LLC and serves as a Principal Partner responsible for pharmaceutical development consulting following retirement from Merck &Co. Inc in 2017. He joined Merck in 2004 as Vice President of Global Safety Assessment. From September of 2010, he served as Global Head of Safety Assessment and Laboratory Animal Resources for Merck Research Laboratories with global responsibility for non-clinical safety testing and evaluation in support of pharmaceutical discovery and development and from November of 2016 as Vice President, Preclinical Development Drug Safety. He has served on or chaired committees on drug discovery, drug candidate selection, early and late development, and development and post marketing drug safety. In addition to his position with Merck, he also serves as the PhRMA Coordinator for ICH Safety Topics (2004-present) and has participated in development of numerous ICH Guidances as PhRMA’s representative on ICH Safety and Multidisciplinary Expert Working Groups. He is a Council member for Institute of Laboratory Animal Research (ILAR) at the National Academy of Sciences, and has served on the Environmental Protection Agency Science Advisory Boards, most recently as a toxicology expert on Hydraulic Fracturing Water Quality Research Advisory Panel.
Before joining Merck, he served as Vice President of Preclinical Safety Evaluation at Novartis Pharmaceuticals and as the Global Chair for the Research and Development Safety Assessment Committee, with responsibility for oversight of first in human studies. Prior to Novartis, he was employed at the Food and Drug Administration (FDA) (1989-2002), where he held the position of Associate Director for Pharmacology and Toxicology in the Center for Drug Evaluation and Research (1996-2002) with responsibility for pharmacology and toxicology policy development and implementation. During his tenure at FDA he served on numerous policy and technical committees: Chair for CDER's Carcinogenicity Assessment Committee, CDER's Pharmacology and Toxicology Coordination Committee, the preclinical lead for the FDA Genomics and Proteomics Task Force, as a member of the International Life Sciences Institute (ILSI) Risk Science Institute Thresholds Assessment Committee, the ILSI-Health and Environmental Sciences (HESI) Alternatives to Carcinogenicity Testing Committee and the ILSI-HESI Emerging Issues Committee, as CDER’s technical representative to the Presidential Commission on Risk Assessment and CDER’s lead to the NIEHS-National Toxicology Program Academia, Industry, and Government Partnership for Evaluation and Validation of Transgenic Models for Carcinogenicity Testing. He also was CDER's ICH Safety Coordinator and lead for numerous Safety Expert Working Groups (1994 - 2002).
Dr. DeGeorge was a Senior Staff Fellow at the National Institutes of Health, National Institute on Aging, Laboratory of Neurosciences, where he worked on development of in vivo functional and structural brain imaging probe. He held a received postdoctoral training as a Fellow at the University of North Carolina, Chapel Hill, NC with a joint appointment at the Burroughs Wellcome Research Institute, Research Triangle Park, NC, where he focused on neural cell signaling and second messenger systems. Dr. DeGeorge received his Ph.D. in Pharmacology from the State University of New York/Upstate Medical Center, and his B.S. in Biology at the State University of New York, Albany.
Dr. Michael DuVall joined Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson in 2012 and is currently a Scientific Director and the US Head Toxicology and Laboratory Animal Medicine. Before joining Johnson & Johnson, Dr. DuVall was an Associate Director and Toxicology Project Lead in Preclinical Safety Evaluation at Abbott Laboratories and a Toxicology Study Director at Covance Laboratories. Michael received his DVM from Texas A&M University (1988) and his PhD from the College of Veterinary Medicine at the University of Minnesota (1993). He completed his post-doctoral training in the Cystic Fibrosis Center and Department of Anesthesiology at the University of Alabama at Birmingham where he studied the effects of reactive oxygen and nitrogen species on epithelial chloride and sodium channel protein function. Throughout his professional career, Michael has been a strong advocate of the ethical use of animals in research and has been active on multiple IACUCs. He is currently the Chairman of the Johnson & Johnson Animal Care and Use Council.
Dr. Lewis B. Kinter is currently President and Principal Scientist at GLP Scientific Consulting, Unionville, PA, USA. He has been engaged in pharmaceutical, biological, and medical device research and development for over 30 years and is an internationally recognized expert in nonclinical R&D. Dr. Kinter received his BS in Biology at Union College (1973) and his doctorate in Medical Physiology from Harvard University (1978). From 1981 to 2014 he held positions of increasing responsibility in biomedical R&D with Smith Kline & French, SmithKline Beecham, Sterling Winthrop, Nycomed Amersham, Astra Merck, and AstraZeneca. Dr. Kinter is a Diplomate of the American Board of Toxicology, Fellow of the Academy of Toxicological Sciences, Professor of Pharmacology & Toxicology (Adjunct) Michigan State University, and has authored over 100 research manuscripts and book chapters in basic and applied physiology, pharmacology, and toxicology. Dr. Kinter serves in leadership capacities on several Boards of professional scientific and charitable organizations.
Dr. Paul A. Locke, an environmental health scientist and attorney, is an Associate Professor at the Johns Hopkins Bloomberg School of Public Health in the Department of Environmental Health and Engineering. He holds a joint appointment in the Department of Health Policy and Management. Dr. Locke has an MPH from Yale University School of Medicine, a DrPH from the Johns Hopkins University Bloomberg School of Public Health and a JD degree from Vanderbilt University School of Law. At Hopkins, Dr. Locke leads an integrated research, practice and teaching program. His program focuses on research-to-practice initiatives to better protect public health, especially in advancing evidence-based in vitro toxicology and radiation protection policy at federal and international organizations. He has published widely in both law reviews and scientific and policy journals, and has developed three cross-disciplinary courses in environmental law and policy and animal law. Dr. Locke also directs the School’s Doctor of Public Health program in Environmental Health Sciences and a certificate program in Humane Sciences and Toxicology Policy. Dr. Locke is admitted to practice law in the state of New York and the District of Columbia, the Southern District Court of New York and is a member of the bar of the United States Supreme Court. He is also a member of the Science Board of the American Public Health Association (APHA). He is the recipient of the Yale School of Public Health Alumni Service Award and the American Public Health Association Environment Section Distinguished Service Award.
Dr. James Roth is a Clarence Hartley Covault Distinguished Professor in the Department of Veterinary Microbiology and Preventative Medicine in the College of Veterinary Medicine at Iowa State University. He received DVM (1975) and PhD (1981) degrees from ISU. He is the Director of the Center for Food Security and Public Health, an OIE Collaborating Center for Day One Veterinary Competencies and Continuing Education, and the Institute for International Cooperation in Animal Biologics, an OIE Collaborating Center for Diagnosis of Animal Disease and Vaccine Evaluation in the Americas. Dr. Roth's primary area of research expertise is immunity to infectious diseases of food-producing animals. Dr. Roth received the Distinguished Veterinary Microbiologist Award from the American College of Veterinary Microbiologists, The Distinguished Veterinary Immunologist Award from the American Association of Veterinary Immunologists, the Public Service Award from the American Veterinary Medical Association and the USDA APHIS Administrator's Award for lifetime achievements in animal health. He has testified before Congress on biosecurity preparedness and efforts to address bioterrorism and agroterrorism. Dr. Roth served on the National Science Advisory Board for Biosecurity from its inception in 2005 until 2014. He was elected to the National Academy of Medicine in 2016.
Dr. Lawrence B. Schook is an Edward William and Jane Marr Gutsgell Professor of Animal Sciences and Radiology and previously served as the Vice President for Research at the University of Illinois, overseeing the technology commercialization and economic development activities across the University’s three campuses (Urbana-Champaign, Chicago, Springfield). Schook is a recognized international scholar in comparative genomics and is known for leading the pig genome-sequencing project, which has provided researchers insights into human cancer and other chronic diseases. He is a noted entrepreneur who has launched two medical application startup companies and is a Fellow at the Academy for Entrepreneurial Leadership. He has served as an advisor to corporations, universities, and government agencies with respect to medical models, genomics, and animal biotechnology. Schook led the effort to develop UI LABS, a Chicago-based research and commercialization collaborative that spun out of the University, and is a founding Board member. He currently serves on the Boards of Trustees for Albion College, the National Academy of Sciences Institute for Laboratory Animal Science Council, the Current Water Innovation Cluster Board, and the Illinois Technology Association Internet of Things Council. He is a member of the Joint Center for Energy Storage Research (JCESR) Governance Board and co-chairs the Chicago Metro Metals Consortium’s Research & Innovation Subcommittee and the Illinois Manufacturing Laboratory Executive Committee. He previously served on the Board of Managers for the Fermi and Argonne National Laboratories, Illinois Governor Quinn’s Innovation Council, the Biotechnology Industry Organization (BIO) Board of Directors, the BIO Governing Board on Food and Agriculture, the Agricultural Biotechnology International Conference Foundation, and the boards of multiple biotechnology companies. He served as Chair for the International Swine Genome Sequencing Consortium, a pig genome sequencing collaboration among global academic, government, and industry representatives. Schook attended Albion College (BA, 1972; Distinguished Alumni Award, 1996) and received his MS and PhD from Wayne State University School of Medicine. He is an elected Fellow of the American Association for the Advancement of Science and was a Fulbright Distinguished Chair in genomics at the University of Salzburg. He has mentored 75 students and 20 postdoctoral fellows, has written more than 250 published works, has edited six books, and is founding editor of Animal Biotechnology.